Tongue News and Research

RSS

Meda launches EDLUAR in the U.S.

Meda Pharmaceuticals Inc. (Meda) today announced the commercial availability of EDLUAR(TM) (zolpidem tartrate sublingual tablets) in the United States. EDLUAR is indicated for the short-term treatment of insomnia characterized by difficulties with falling asleep. EDLUAR is the first available under-the-tongue formulation of zolpidem tartrate, which is the most prescribed treatment for insomnia. Zolpidem tartrate is also the active ingredient in Ambien(R) oral tablets.

9 Sep 2009

Obama set to reveal specific health reform details in strategy shift

After an August recess that saw Democrats take a beating on their message and calls from lawmakers to provide more leadership, President Obama is likely to change course on his approach to health reform legislation.

3 Sep 2009

FDA approves Extavia for multiple sclerosis

The US Food and Drug Administration (FDA) has approved Extavia(R) (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis to help patients manage this devastating disease.

17 Aug 2009

Alarming rise in oral cancer rates among forty-somethings

Rates of oral cancers, such as cancers of the mouth, tongue and lip, have increased by around a quarter in the past decade among people in their 40s, according to figures from Cancer Research UK.

12 Aug 2009

Orexo: Abstral NDA submitted to U.S. FDA

Orexo AB has announced that its partner, UK-based international specialty pharmaceutical company ProStrakan Group plc, has submitted the New Drug Application (NDA) for Abstral™ (for the treatment of breakthrough cancer pain in opioid-tolerant patients) to the US Food and Drug Administration (FDA).

6 Aug 2009

Airway cells are chemosensory

The same mechanism that helps you detect bad-tasting and potentially poisonous foods may also play a role in protecting your airway from harmful substances, according to a study by scientists at the University of Iowa Roy J. and Lucille A. Carver College of Medicine.

24 Jul 2009

Xerostomia linked to use of multiple medications

Approximately ninety-one percent of dentists say patients complaining about dry mouth are taking multiple medications, according to a nationwide member survey conducted by the Academy of General Dentistry (AGD).

9 Jul 2009

Study shows that induction chemotherapy prior to chemoradiotherapy significantly increases time-to-treatment failure in comparison to standard chemoradiotherapy alone

The Spanish Head and Neck Cancer Cooperative Group (TTCC) announced today that Induction Chemotherapy (IC) delivered prior to standard ChemoRadiotherapy (CRT), a treatment paradigm defined as sequential therapy, compared to upfront CRT alone, significantly prolonged Time-to-Treatment Failure (TTF) for patients with unresectable Locally Advanced Head and Neck Cancer (LAHNC).

1 Jun 2009

Call for vaccination against HPV 16 in young men and women to prevent head and neck cancers

Researchers at Roswell Park Cancer Institute (RPCI) in Buffalo, New York, are strongly advocating a national discussion about the need to vaccinate both young men and women against HPV 16 to prevent head & neck cancers.

22 May 2009

Study looks at transpalatal advancement pharyngoplasty procedure for sleep apnea

Treatment with surgery or an oral appliance that adjusts the jaw is associated with improvements in obstructive sleep apnea, a condition caused by blocked upper airways in which patients periodically stop breathing during sleep, according to two reports in the May issue of Archives of Otolaryngology–Head & Neck Surgery.

18 May 2009

Sufferers of mild to moderate obstructive sleep apnea may benefit from exercise

Practicing certain tongue and pharyngeal exercises may reduce symptoms of mild to moderate obstructive sleep apnea (OSA), according to new research being published in the second issue for May of the American Journal of Respiratory and Critical Care Medicine.

7 May 2009

Sublingual immunotherapy for inhalant allergies deserves deeper consideration

Sublingual immunotherapy for the treatment of allergy symptoms caused by a wide variety of environmental inhalants has been effectively used in Europe.

30 Apr 2009

AcelRx starts cancer breakthrough pain program

AcelRx Pharmaceuticals, Inc. has announced that it has initiated a Phase 2 clinical trial of ARX-02, a proprietary sublingual sufentanil NanoTab product candidate for cancer breakthrough pain control.

22 Apr 2009

AEterna Zentaris presents results for AEZS-112 in advanced cancer and lymphoma

AEterna Zentaris Inc. has presented a poster outlining Phase 1 results for its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in patients with advanced solid tumors or lymphoma, which may potentially provide a new therapeutic approach for the treatment of cancer.

22 Apr 2009

Acupuncture relieves symptoms of xerostomia

Twice weekly acupuncture treatments relieve debilitating symptoms of xerostomia - severe dry mouth - among patients treated with radiation for head and neck cancer, researchers from The University of Texas M. D. Anderson Cancer Center report in the current online issue of Head & Neck.

20 Apr 2009

Cancer vaccines receive orphan drug designation for advanced head and neck cancer

Two experimental vaccines from the University of Maryland, Baltimore (UMB) recently received a federal orphan drug designation for advanced head and neck cancer, according to a company official.

9 Apr 2009

Researchers find an increased rate of unintentional injection of epinephrine from auto-injectors for anaphylaxis

Researchers find an increased rate of unintentional injection of epinephrine from auto-injectors for anaphylaxis (severe allergic reactions) and urge people who may need to administer the life-saving drug to themselves or others in an allergic emergency to receive regular coaching in its proper use.

6 Apr 2009